Kornimate/medical-research-clean huggingface dataset:
effect of dental educational program on oral hygiene status among institutionalized deaf children

Conditions: Hearing Loss

Summary: assess the effect of dental educational program on oral hygiene among institutionalized hearing impaired and mute children in cairo, egypt.

* evaluate participants satisfaction regarding the dental educational program(learning teeth brushing technique) * measure the oral hygiene index simplified to the participants at a different follow up periods for assessing the effect of the dental educational program on oral hygiene.

Eligibility criteria:
inclusion criteria: * children aged from 6-12 years with mixed dentition. * institutionalized deaf children in cairo, egypt. exclusion criteria: * children above the age of 12 years and below the age of 6 years * patient un able to give informed consent * patient suffering from any other type of disability such as (mental retardation, physically and mentally handicapped, .etc.) * medically compromised patient * patient who were absent in the day of examination
immunogenicity of hepatitis b vaccination in hemodialysis patients

Conditions: Hepatitis B Vaccine

Summary: intramuscular injection of 40 μg hepatitis b vaccine in a standard three-dose schedule or a four-dose schedule is recommended for hemodialysis patients. however, seroconversion rates are inadequate and persistence of immunity remains a challenge. this is a randomized, controlled trial. the study will evaluate the immunogenicity, immune persistence, and safety of 20 µg and 60 µg recombinant hepatitis b vaccine with three injections at months 0, 1, and 6 in hemodialysis patients.

participants are randomized in a ratio of 1:1 into 20 µg recombinant hepatitis b vaccine group or 60µg recombinant hepatitis b vaccine group.the 20 µg group will receive three intramuscular injections of the 20 µg recombinant hepatitis b vaccine, while the 60 µg group will receive three intramuscular injections of the 60 µg dose at months 0, 1 and 6, respectively. hbsag and anti-hbs will be tested during the study period. adverse reactions will be recorded after vaccination.

Eligibility criteria:
inclusion criteria: * having end-stage renal disease (esrd) on maintenance hemodialysis * aged between 18 and 70 years at enrollment * serologically negative for hepatitis b surface antigen (hbsag) and hepatitis b surface antibody (anti-hbs) at enrollment * willing to adhere to the study protocol exclusion criteria: * being pregnant * acute cytolysis in the last three months before enrollment * any vaccination during the month preceding enrollment * intolerance or allergy to any component of the vaccine * ongoing opportunistic infection * hepatitis c virus infection * hematological disorder * cancer * unexplained fever the week before enrollment * immunosuppressive or immunomodulating treatment in the last six months * renal transplantation or upcoming renal transplantation * liver disease * other immunocompromised condition not related to esrd * an expected survival of \< 6 months

Keywords: hepatitis b, vaccine randomized controlled trial hemodialysis immunogenicity
propofol for treatment on emergence agitation

Conditions: Child; Anesthesia Morbidity

Summary: this study aimed to verify the effects of propofol for treatment on emergence agitation (ea) after sevoflurane anesthesia in pediatric strabismus surgery.

sevoflurane with rapid anesthetic induction and emergence, hemodynamic stability, and nonirritating airway properties, has acquired widespread acceptance in children. however, sevoflurane has been reported to be associated with emergence agitation in children, with a reported incidence of up to 80%. in severe case, it cause injury to the child or to the surgical site and lead to the accidental removal of surgical dressings and intravenous catheters. in case of intense agitation with high risk of self-injury, pharmacologic intervention seems reasonable. pharmacologic treatment of emergence agitation relies on the administration of iv sedative agents (iv midazolam 0.1 mg/kg12 or propofol 0.5 or 1 mg/kg) or opioid agents (iv fentanyl 1 or 2 mcg/kg). however, these treatments are empirical and were extrapolated from pharmacologic preventive studies performed at the end of surgery or from personal experience. to the investigators knowledge, there is no risk of recurrence of ea after a first episode. consequently, ea is not per se a factor of increased duration of pacu (post-anaesthesia care unit ) stay, but sedative or opioid agents administered postoperatively to alleviate it might prolong this stay. therefore, the investigators design a study to confirm statistically effect of propofol for treatment on emergence agitation after sevoflurane anesthesia in pediatric strabismus surgery through paed scale. furthermore duration of pacu stay is checked after propofol administration.

Eligibility criteria:
inclusion criteria: * asa (american society of anesthesiologists) physical status patients, aged 3-10yr, presenting for elective strabismus surgery. exclusion criteria: * refusal by parents, neurologic disease, developmental delay, history of any previous surgery, american society of anesthesiologists physical status score of iii or iv, and airway disease

Keywords: emergence agitation emergence delirium paed scale the modified aldrete scoring system treatment pediatric sevoflurane
effects of rhinopharyngeal retrograde clearance in children with acute viral bronchiolitis

Conditions: Acute Viral Bronchiolitis

Summary: the purpose of this study is to compare the immediate effects of retrograde rhinopharyngeal clearance with nasopharyngeal aspiration in children admitted with acute viral bronchiolitis. the investigators selected children, up to 12 months old, admitted for acute viral bronchiolitis. patients were divided in aspiration group (ag), submitted to nasopharyngeal aspiration, and clearance group (cg), submitted to retrograde rhinopharyngeal clearance with physiological solution (0.9%) instillation (rrc) technique. in both groups children were evaluated three times in the same day in order to verify cardiorespiratory parameters, clinical score of respiratory dysfunction and adverse effects.

children up to 12 months old, admitted for acute viral acute viral bronchiolitis were selected. all children participating in the study should be in the first 48 hours of hospitalization. patients were divided in aspiration group (ag), submitted to nasopharyngeal aspiration, and clearance group (cg), submitted to retrograde rhinopharyngeal clearance (rrc) technique with physiological solution (0.9%) instillation. in both groups children were evaluated three times in the same day (data collection 1 (c1) - performed early in the morning; data collecting 2 (c2) - performed in the early afternoon; and data collecting 3 (c3) - performed in the evening). in each data collection, cardiorespiratory parameters and clinical score of respiratory dysfunction were evaluated before procedures (t0), 10 minutes after (t1) and 30 minutes after (t2). adverse effects were evaluated during the whole day of the study.

Eligibility criteria:
inclusion criteria: * acute viral bronchiolitis diagnosis * indication for hospital admission exclusion criteria: * history of lung disease related to prematurity (bronchopulmonary dysplasia) * heart diseases * chronic lung diseases (cystic fibrosis) * pneumonia * unstable hemodynamic process (ards or sepsis) * subcutaneous edema * admission to the intensive care unit * need for mechanical ventilation or tracheostomy * neurological diseases

Keywords: bronchiolitis respiratory physiotherapy pediatrics rhinopharyngeal clearance
intracameral versus intravitreal bevacizumab injection in nvg: rct

Conditions: Glaucoma, Neovascular; Vascular Endothelial Growth Factor Overexpression

Summary: to prospect studying the efficacy and safety of treating nvg with the intracameral versus the intravitreal injection of bevacizumab.

the present study comparing the safety and efficacy of 1.25mg/0.05ml bevacizumab injection via the intracameral route versus the intravitreal route in treating the neovascular glaucoma

Eligibility criteria:
inclusion criteria: 1. diagnosis of neovascular glaucoma 2. the patients having iop \> 21 mmhg, having the indication for trabeculectomy 3. the patients' age of at least 18-year-old 4. the patients having visual potential at least hand motion. 5. present of nvi or nva. 6. willing and able to provide informed consent to participate in the study 7. able to understand the purpose of the study, his/her role, and is available to return to the clinic/hospital for all required follow-up visits exclusion criteria: 1. one eye patient 2. patients having severe corneal edema or total hyphema obscure nvi or nva view. 3. cannot obtain endothelial cell count. 4. history of bevacizumab or fluorescence dye allergy. 5. active infectious ocular disease including endophthalmitis and corneal ulcer 6. history of systemic disease including ischemic heart disease, cerebrovascular disease, end-stage renal disease, liver failure, uncontrolled hypertension 7. has or planning to be pregnant or breastfeeding

Keywords: neovascular glaucoma
hydration and contrast-induced nephropathy in primary angioplasty

Conditions: Contrast Induced Nephropathy

Summary: the purpose of this study is to determine whether hydration with sodium bicarbonate is more effective than hydration with sodium chloride to prevent contrast induced nephropathy in patients undergoing primary coronary intervention for acute st elevation myocardial infarction.


Eligibility criteria:
inclusion criteria: * patients with acute st elevation myocardial infarction submitted to primary intervention exclusion criteria: * refusal to consent * previous contrast exposure within 72 hours

Keywords: contrast induced nephropathy
a phase ib/ii clinical trial of lbl-007 combined with tislelizumab in the treatment of malignant tumors

Conditions: Malignant Tumors

Summary: this trial is an open and multicenter phase ib/ii clinical study, which aims to evaluate the safety, tolerability, pk characteristics, immunogenicity, and effectiveness.

this is an open, multicenter phase ib/ii clinical trial of lbl-007 combined with tislelizumab in the treatment of malignant tumors，which aims to evaluate the safety, tolerability, pk characteristics, immunogenicity, and effectiveness. the study was divided into two phases: phase ib (part a): dose escalation and pk expansion; phase ii includes: part b, part c, part d, part e, part f, part g, part h. part b \~ part h will be designed and conducted based on the safety , tolerability and pk analysis of the part a study part, after rp2d is determined, will be used for part b \~ part h cohort. approximately 250-490 subjects will be enrolled (specific sample size shall be subject to actual occurrence)

Eligibility criteria:
inclusion criteria: 1. agree to follow the experimental treatment plan and visit plan, join the group voluntarily, and sign a written informed consent form; 2. age ≥ 18 and ≤ 75 years old when signing the informed consent form, regardless of gender; 3. the eastern cooperative oncology group's physical status scoring standard (ecog) ps is 0\~1; 4. the expected survival time is at least 12 weeks; 5. according to the evaluation criteria for the efficacy of solid tumors (recist 1.1), the subjects enrolled have at least one measurable tumor lesion; 6. subject has adequate organ and bone marrow function 7. males with fertility and females of childbearing age are willing to take effective contraceptive measures (including abstinence, intrauterine device, various hormonal contraception, correct use of contraception from the signing of the informed consent form to 6 months after the last administration of the trial drug sets, etc.); women of childbearing age include pre-menopausal women and women within 2 years after menopause. women of childbearing age must have a negative pregnancy test within 7 days before the first trial drug is administered. exclusion criteria: 1. have received other unmarketed clinical research drugs or treatments within 4 weeks before using the research drug for the first time; 2. those who have clinically uncontrollable pleural effusion, pericardial effusion or ascites, requiring repeated drainage or medical intervention; 3. women during pregnancy or lactation; 4. the investigator believes that the subject has other conditions that may affect compliance or are not suitable for participating in this study. 5. patients with history of severe cardiovascular and cerebrovascular diseases. 6. patients with active infection and currently requiring intravenous anti-infective treatment
the difference of weight gain tendencies and obesity during pregnancy

Conditions: Obesity, Maternal; Weight Gain, Maternal; Birth Weight; Birth Outcome, Adverse

Summary: background: excess weight and obesity are a global pandemic, particularly among women of childbearing age. pre-pregnancy obesity is linked to adverse maternal and neonatal outcomes, including preterm birth, macrosomia, stillbirth, and neonatal death. these risks vary by maternal age, race, and ethnicity, with rising rates among immigrant and minority women. this study investigates overweight and obesity rates in pregnant women, weight gain during pregnancy, and adherence to guidelines and possible neonatal outcomes, comparing turkish and syrian immigrant women. methods: this retrospective single-center study was conducted at buca seyfi demirsoy teaching and research hospital in izmir, turkey, over one year. data collected included demographic information, pregnancy complications, delivery modes, maternal and neonatal anthropometric measurements, and neonatal morbidity and mortality. the study included turkish and syrian women with complete medical records. statistical analyses were performed using spss software, with significance set at p \< 0.05.

background: excess weight and obesity are a global pandemic, particularly among women of childbearing age. pre-pregnancy obesity is linked to adverse maternal and neonatal outcomes, including preterm birth, macrosomia, stillbirth, and neonatal death. these risks vary by maternal age, race, and ethnicity, with rising rates among immigrant and minority women. this study investigates overweight and obesity rates in pregnant women, weight gain during pregnancy, and adherence to guidelines and possible neonatal outcomes, comparing turkish and syrian immigrant women. methods: this retrospective single-center study was conducted at buca seyfi demirsoy teaching and research hospital in izmir, turkey, over one year. data collected included demographic information, pregnancy complications, delivery modes, maternal and neonatal anthropometric measurements, and neonatal morbidity and mortality. the study included turkish and syrian women with complete medical records. statistical analyses were performed using spss software, with significance set at p \< 0.05.

Eligibility criteria:
inclusion criteria: * being admitted to our hospital for delivery or having just given birth * being turkish or syrian * having all detailed information, including mothers' pregestational and immediate pre-delivery body weights, available in medical records exclusion criteria: * significant deficiencies in medical records * belonging to an ethnic group other than turkish or syrian

Keywords: maternal obesity neonatal outcome weight gain in pregnancy immigrant syrian turkish
3d printed mask adapter designed from facial 3d scans for fit testing.

Conditions: COVID-19 Pandemic

Summary: healthcare workers ppe (personal protective equipment) when interacting with patients either infected or, potentially carrying sars-cov-2. one of the major routes of transmission is via droplet spread through oral and nasal mucosa therefore respiratory protective equipment (rpe) is an important part of ppe. there are concerns in dentistry that droplet spread can be increased during aerosol-generating procedures (agp). this poses an increased risk to dentists and allied professionals in a clinical setting. fit testing is needed to ensure a mask forms a facial seal around the mouth and nose. using a respirator mask without fit testing can reduce its effectiveness from between 6-88% with an optimal facial seal being more critical than the filtering performance. commercial respirator masks are mass-produced for ' standard' faces, and often fail to provide a good fit for users thereby compromising the intended respirator filtering capability. given the high level of fit test failures, without the provision of improved fits of masks, patient care will be highly curtailed for frontline staff at risk of sars-cov-2. therefore, a reusable bespoke 3d printed mask adapter used with a soft ffp3 disposable mask provides an economical solution to address the passing of fit testing. barts health nhs trust staff members who have previously failed the fit test to the first line ffp3 disposable respirator will be invited to enrol in this study. barts/qmul scan app will be used to capture the facial scan of the subjects using a research allocated smartphone. participants will be asked to be clean-shaven without any facial jewellery which could hinder the scan data. the app automatically generates a customized 3d print file (.stl) which will be sent for 3d printing. the mask adapter will be fitted over the first-line ffp3 respirator once it is properly worn and checked as per the procedure.


Eligibility criteria:
inclusion criteria: * subjects who would have previously failed the quantitative fit test on the trust's first line ffp3 disposable respirator. * subjects willing to use a flexible, disposable ffp3 mask. * subjects should be a minimum of 18 years old. exclusion criteria: * subjects unwilling or unable to give written consent. * subjects who cannot remove their facial hair for religious or other reasons.
enhancing resilience in senior living community residents

Conditions: Stress, Psychological; Coping Skills

Summary: this single-arm pilot study tests the feasibility of integrating the stress management and resiliency training relaxation response resiliency program (smart-3rp), a mind-body intervention, into senior living residential communities. the investigators hypothesize that the smart-3rp intervention will be feasible for senior living community residents to attend.


Eligibility criteria:
inclusion criteria: * resident of an erickson living senior living community * currently residing in an erickson living apartment home * sufficient english language skills to participate in study procedures exclusion criteria: * unable or unwilling to provide informed consent * unable or unwilling to participate in group sessions

Keywords: resiliency flourishing coping skills stress reduction healthy aging
chemotherapy in treating patients with unresectable primary or metastatic kidney cancer

Conditions: Liver Cancer; Metastatic Cancer

Summary: rationale: drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. purpose: phase ii trial to study the effectiveness of pyrazoloacridine in treating patients who have unresectable primary or metastatic kidney cancer that has not been previously treated.

objectives: i. determine the response rate, duration, and survival in previously untreated patients with hepatocellular carcinoma treated with pyrazoloacridine (pza). ii. determine the nature, degree, and duration of toxic effects of pza in these patients. outline: patients receive pyrazoloacridine iv over 3 hours every 3 weeks. the minimum treatment period is 2 courses with tumor restaging at 6 weeks. patients with complete remission (cr) or partial remission (pr) may continue on treatment until refractory (pr) or for at least 3 additional courses (cr). patients with stable disease continue on therapy for at least 2 more courses. patients are followed until death. projected accrual: a total of 12-37 patients will be accrued for this study within 24 months.

Eligibility criteria:
disease characteristics: histologically proven unresectable primary or metastatic hepatocellular carcinoma measurable disease by ct or mri scan no tense ascites brain metastases allowed with proper treatment patient characteristics: age: not specified performance status: karnofsky 70-100% zubrod 0-2 life expectancy: at least 12 weeks hematopoietic: absolute granulocyte count at least 1,500/mm3 platelet count at least 100,000/mm3 hepatic: bilirubin no greater than 1.5 mg/dl albumin at least 3 g/dl alkaline phosphatase no greater than 3 times upper limit of normal renal: creatinine no greater than 1.5 mg/dl other: not pregnant or nursing fertile patients must use effective contraception no significant infection peripheral neurologic toxicity limited to paresthesia and decreased vibratory sense without motor weakness allowed constipation managed with laxatives without evidence of bowel obstruction allowed no psychological disorders including delirium, confusion, suicidal ideation, or untreated depression prior concurrent therapy: biologic therapy: not specified chemotherapy: no prior chemotherapy endocrine therapy: not specified radiotherapy: prior palliative radiotherapy allowed at least 3 weeks since prior radiotherapy and recovered surgery: recovered from any prior surgery

Keywords: localized unresectable adult primary liver cancer advanced adult primary liver cancer adult primary hepatocellular carcinoma liver metastases
a study of olanzapine-samidorphan tablets in adults with schizophrenia

Conditions: Schizophrenia

Summary: the goal of this \[clinical trial\] is to \[evaluate the safety and efficacy of olanzapine-samidorphan tablets\] in \[adults with schizophrenia\]. the main question\[s\] it aims to answer are: * \[question 1\] olanzapine-samidorphan significantly mitigate weight gain better than olanzapine. * \[question 2\] olanzapine- samidorphan and olanzapine have similar antipsychotic efficacy.


Eligibility criteria:
inclusion criteria: * subject is age 18 to 55 years, inclusive. * subject has a bmi of 18.0 to 30.0 kg/m2, inclusive. * subject meets the dsm-5 criteria for a primary diagnosis of schizophrenia. * panss total score ≥ 70. exclusion criteria: * diagnosis of schizoaffective disorder or bipolar i or ii disorder, or current, untreated or unstable major depressive disorder, or any other psychiatric condition that could interfere with participation in the study. * subject poses a current suicide risk in the opinion of the investigator. * subject has inflammatory bowel disease or any other gastrointestinal disorder associated with weight loss, anorexia nervosa, or binge eating disorder. * subject has a history of diabetes. * subject has used olanzapine, clozapine, chlorpromazine, or thioridazine at any time during the 6 months prior to screening or long-acting injectable antipsychotic medication in the last 6 months. * subject has taken opioid agonists within the 14 days prior to screening and/or anticipates a need to take opioid medication during the study period, or has taken opioid antagonists within 60 days prior to screening. * subject is taking any weight loss agents or hypoglycemic agents at screening. * subject has had a surgical procedure for weight loss or is planning to have liposuction during the study. * subject has a clinically significant or unstable medical illness, condition, or disorder that would be anticipated to potentially compromise subject safety or adversely affect the evaluation of efficacy.